Cargando…
Cross-validation of genes potentially associated with neoadjuvant chemotherapy and platinum-based chemoresistance in epithelial ovarian carcinoma
Ovarian carcinomas have the poorest prognosis and the highest mortality among gynecological malignancies. Neoadjuvant chemotherapy (NACT) is considered as a novel therapeutic strategy and an alternative treatment for advanced epithelial ovarian cancer (AEOC). The aim of the present study was to iden...
Autores principales: | Zhang, Kai, Wang, Weihan, Chen, Lingli, Liu, Yulin, Hu, Jiali, Guo, Fei, Tian, Wenyan, Wang, Yingmei, Xue, Fengxia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388274/ https://www.ncbi.nlm.nih.gov/pubmed/32705213 http://dx.doi.org/10.3892/or.2020.7668 |
Ejemplares similares
-
Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016) -
Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022) -
Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
por: Pelissier, Aurélie, et al.
Publicado: (2016) -
Leptin contributes to the taxol chemoresistance in epithelial ovarian cancer
por: Gu, Fei, et al.
Publicado: (2019) -
The Hippo pathway in endometrial cancer: a potential therapeutic target?
por: Shen, Xinyun, et al.
Publicado: (2023)